Posts tagged “Novartis”
Daniel Vasella, who is stepping down as chairman of international drug firm Novartis and decided not to accept a $78 million non-compete agreement, is now talking with the company about a consulting role.
As drug maker Novartis goes through a change at the top with Chairman Daniel Vasella stepping down, investors celebrate the move and call for the company to spin off some assets such as its vaccine business.
The U.S. Food and Drug Administration gives approval for a seasonal influenza vaccine produced at Novartis' new, huge production facility in Holly Springs.
Patients taking Novartis's QVA149 were able to expel more air from their lungs in one second than those receiving Glaxo's best-selling Advair after 26 weeks of treatment, according to a summary of data from a trial.
If successful, LCZ696 would be the first drug for patients with preserved ejection fraction, a condition in which the organ's ventricles still pump out more than 40 percent of the blood that comes in, but the atrium chamber fails to supply enough blood to the ventricle to meet the body's needs. The condition, which mainly affects women, accounts for about half of all heart failure patients.
Novartis along with Duke and NCSU will create a center for biodefense and to combat pandemic influenza in Holly Springs under a $60 million contract with the U.S. Department of Health and Human Services. GSK will work with Texas A&M on a $176 million deal.
NC biotech group hails formal dedication of the massive $1 billion Novartis plant in Holly Springs.
The U.S. Food and Drug Administration is taking Novartis CEO Joseph Jimenez to task with a warning letter that cites three of the company's manufacturing facilities for "significant violations" at the company's generics drug unit Sandoz.
The drug giant, which operates a huge vaccine production and research facility in Holly Springs, says some jobs will be moved to the US as well as China and India.
The movie "Contagion" is fiction, but ask Novartis executive Russell Thirsk and he'll tell you the threats it depicts are quite real.
In a case that could affect India's role as drug provider to the developing world, the Supreme Court began hearing arguments Tuesday over whether the government had the right to deny a patent to Swiss drugmaker Novartis AG for its lifesaving cancer treatment Gleevec.
The global life sciences firm will receive up to $3.7 million in state tax incentives for the expansion.